Kingswood Wealth Advisors LLC lowered its stake in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 33.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,265 shares of the company's stock after selling 1,606 shares during the quarter. Kingswood Wealth Advisors LLC's holdings in HCA Healthcare were worth $980,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Legacy Investment Solutions LLC purchased a new stake in HCA Healthcare in the third quarter worth about $39,000. Capital Performance Advisors LLP purchased a new stake in HCA Healthcare in the third quarter worth about $41,000. Canoe Financial LP purchased a new stake in HCA Healthcare in the third quarter worth about $41,000. Northwest Investment Counselors LLC purchased a new stake in shares of HCA Healthcare during the third quarter valued at approximately $44,000. Finally, Friedenthal Financial purchased a new stake in shares of HCA Healthcare during the third quarter valued at approximately $50,000. Hedge funds and other institutional investors own 62.73% of the company's stock.
Shares of HCA stock opened at $328.39 on Wednesday. The company has a market capitalization of $83.18 billion, a price-to-earnings ratio of 14.75, a PEG ratio of 1.09 and a beta of 1.64. The company's fifty day moving average price is $313.42 and its 200-day moving average price is $353.24. HCA Healthcare, Inc. has a one year low of $281.61 and a one year high of $417.14. The company has a debt-to-equity ratio of 48.71, a current ratio of 1.12 and a quick ratio of 1.00.
HCA Healthcare (NYSE:HCA - Get Free Report) last posted its earnings results on Friday, January 24th. The company reported $6.22 earnings per share for the quarter, beating the consensus estimate of $6.03 by $0.19. HCA Healthcare had a net margin of 8.52% and a return on equity of 520.98%. During the same quarter in the previous year, the business earned $5.90 earnings per share. Sell-side analysts expect that HCA Healthcare, Inc. will post 21.75 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 17th will be paid a $0.72 dividend. This is a boost from HCA Healthcare's previous quarterly dividend of $0.66. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Monday, March 17th. HCA Healthcare's dividend payout ratio (DPR) is presently 13.11%.
In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of HCA Healthcare stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the transaction, the insider now directly owns 6,843 shares of the company's stock, valued at $2,415,579. This trade represents a 29.76 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Phillip G. Billington sold 3,897 shares of the firm's stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the completion of the sale, the senior vice president now owns 52,702 shares of the company's stock, valued at $18,445,700. This trade represents a 6.89 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.70% of the company's stock.
A number of equities research analysts have recently commented on HCA shares. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $380.00 price target on shares of HCA Healthcare in a report on Tuesday, December 17th. Royal Bank of Canada cut their price target on shares of HCA Healthcare from $405.00 to $384.00 and set an "outperform" rating on the stock in a report on Monday. TD Cowen lowered their price objective on shares of HCA Healthcare from $450.00 to $440.00 and set a "buy" rating on the stock in a research report on Monday, October 28th. Barclays lowered their price objective on shares of HCA Healthcare from $392.00 to $366.00 and set an "overweight" rating on the stock in a research report on Monday. Finally, StockNews.com downgraded shares of HCA Healthcare from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $382.19.
Read Our Latest Report on HCA
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider HCA Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HCA Healthcare wasn't on the list.
While HCA Healthcare currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.